Cognition Therapeutics Reports 32-Cent Per Share Loss for 2025
Summary
Cognition Therapeutics reported a loss of 32 cents per share for the full year 2025. This financial update provides a key data point on the company's operational performance and burn rate. For a small-cap biotech company, managing losses and maintaining a sufficient cash runway are critical, especially as it continues to advance its drug pipeline. This news follows the company's recent announcement of compelling Phase 2 data for its drug zervimesine (CT1812) in Dementia with Lewy Bodies, highlighting the dual focus on clinical progress and financial sustainability. Traders will be looking for the full financial report to assess cash reserves, operating expenses, and any forward guidance.
At the time of this announcement, CGTX was trading at $1.12 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $98M. The 52-week trading range was $0.22 to $3.83. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.